Telum Therapeutics, a Spanish BioTech company, today announced the successful completion of an €18 million Series A financing to advance its lead programme targeting hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP). AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors
Ethan Conroy
Telum Therapeutics, a Spanish BioTech company, today announced the successful completion of an €18 million Series A financing to advance its lead programme targeting hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP).
AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI with its SICC Innvierte, Clave Capital and Sodena.
“We are delighted to welcome AMR Action Fund and Inveready as new investors in Telum. AMR Action Fund’s dedicated focus and deep expertise in antimicrobial resistance, together with the continued support of Invivo Partners, Clave Capital, CDTI-Innvierte and Sodena, reinforces our confidence in the potential of the APEX platform to generate a new class of antimicrobial therapies for difficult-to-treat infections,” says Dr. Subhendu Basu, Chief Executive Officer of Telum Therapeutics.
This announcement sits alongside several sizeable and relevant European BioTech and drug discovery financings this year. The largest adjacent round was Bavaria-based mbiomics’ who raised €30 million Series A total to scale microbiome therapeutics for chronic and severe diseases, while Parisian Generare, a BioTech startup generating novel, high-quality molecular data for drug development, closed a €20 million Series A to expand its microbial-genome-based drug discovery platform was also notable within the sector.
Helical, a virtual AI lab for pharma R&D based in London, raised €8.4 million Seed financing for AI infrastructure. In another Spanish case, Barcelona-based Gate2Brain closed a €7 million round to advance its brain tumour candidate and blood-brain barrier delivery platform, while Finnish Avenue Biosciences, a protein engineering technology company, announced in January a €4.8 million Seed extension to scale protein engineering for therapeutic and BioTech applications.
Taken together with Telum’s announcement, these five comparable rounds represent approximately €88.2 million in disclosed 2026 funding across adjacent European BioTech, therapeutic platform and drug discovery companies, including a same-country comparator in Spain through Gate2Brain.
Telum, which was founded in 2019, has developed a lead programme designed to address severe infections caused by Acinetobacter baumannii, a multidrug-resistant Gram-negative pathogen associated with significant morbidity and mortality in hospitalised patients worldwide.
“This financing provides a clear path to complete Phase 1 development of our lead programme targeting Acinetobacter baumannii HABP/VABP, while also enabling us to advance our broader pipeline addressing both Gram-negative and Gram-positive pathogens,” adds Basu.
This latest investment from AMR Action Fund will enable Telum to advance its lead candidate through Phase 1 clinical development, generating critical safety and translational data to support subsequent stages of clinical evaluation.
“Acinetobacter baumannii is one of the most formidable bacterial threats in modern medicine. It is clinically challenging, often resistant to first-line therapies, and a pathogen for which progress has been slow and difficult to achieve,
“We are encouraged by Telum’s novel approach and pleased to support the team as they work to bring forward a new treatment option for patients with life-threatening infections,” added Dr. Henry Skinner, Chief Executive Officer of the AMR Action Fund.
Built on the Company’s proprietary APEX platform, Telum is developing biologically derived, protein-based antimicrobial therapeutics with the potential to overcome key limitations of existing antibiotic approaches and expand treatment options for patients facing life-threatening infections.
This financing brings together international and Spanish life sciences investors, technology-focused investment funds and public institutions committed to supporting innovation in healthcare. It also highlights the important role of Navarra’s innovation ecosystem in fostering the development of science-driven companies with global ambition.
